A blueprint from nature: miRNome comparison of plasma cells and CHO cells to optimize therapeutic antibody production-Reference-Cited by-同舟云学术

A blueprint from nature: miRNome comparison of plasma cells and CHO cells to optimize therapeutic antibody production

Published:2022-01 Issue: Volume:66 Page:79-88
ISSN:1871-6784
Container-title:New Biotechnology
language:en
Short-container-title:New Biotechnology

Author:

Raab Nadja,Zeh Nikolas,Schlossbauer Patrick,Mathias Sven,Lindner Benjamin,Stadermann Anna,Gamer Martin,Fischer Simon,Holzmann Karlheinz,Handrick René,Otte Kerstin

Funder

Bundesministerium fur Bildung und Forschung Dienststelle Berlin

Bundesministerium für Bildung und Forschung

Publisher

Elsevier BV

Subject

Molecular Biology,General Medicine,Bioengineering,Biotechnology

Reference82 articles.

1. 25 years of recombinant proteins from reactor-grown cells — where do we go from here?;Hacker;Biotechnol Adv,2009

2. The art of CHO cell engineering: a comprehensive retrospect and future perspectives;Fischer;Biotechnol Adv,2015

3. Biopharmaceutical benchmarks 2018;Walsh;Nat Biotechnol,2018

4. Recombinant expression systems in the pharmaceutical industry;Schmidt;Appl Microbiol Biotechnol,2004

5. CHO cells in biotechnology for production of recombinant proteins: current state and further potential;Kim;Appl Microbiol Biotechnol,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Large-Scale Comparative Transcriptomic Analysis of CHO Cell Functional Adaptation to Recombinant Monoclonal Antibody Production;2024-07-01

2. Nature as blueprint: Global phenotype engineering of CHO production cells based on a multi-omics comparison with plasma cells;Metabolic Engineering;2024-05

3. In pursuit of a minimal CHO genome: Establishment of large-scale genome deletions;New Biotechnology;2024-03

4. Recombinant therapeutic proteins degradation and overcoming strategies in CHO cells;Applied Microbiology and Biotechnology;2024-01-29

5. Developing microRNAs as engineering tools to modulate monoclonal antibody galactosylation;Biotechnology and Bioengineering;2023-12-11